June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
C, L. K
Author:
C. R,
Author:
Caballero, D.

S869 TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T-CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE 2 STUDY

Witzig, T.; Sokol, L.; Kim, W.S.; More

HemaSphere. 3(S1):389, June 2019.

S1622 TANDEM AUTOLOGOUS-REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN HIGH-RISK RELAPSED HODGKIN LYMPHOMA: A RETROSPECTIVE STUDY OF THE LWP-EBMT

Bento, L.; Boumendil, A.; Fine, H.; More

HemaSphere. 3(S1):749-750, June 2019.

Author:
Caballero, G.

PS1186 CURRENT DOSE RECOMMENDATIONS FOR PONATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS CAN DIMINISH ADVERSE EVENTS WHILE MAINTAINING EFFICACY

Garcia-Gutierrez, V.; Hernandez-Boluda, J.C.; Moiraghi, B.; More

HemaSphere. 3(S1):540-541, June 2019.

PS1391 ASSESSMENT OF THE BURDEN OF DISEASE IN TERMS OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MULTIPLE MYELOMA NOT ELIGIBLE FOR ASCT IN SPAIN: INTERIM ANALYSIS OF QOLMMBUS STUDY

de la Rubia, J.; Domingo, A.; Delgado, O.; More

HemaSphere. 3(S1):638, June 2019.

PB2080 ROLE OF SOMATIC MUTATIONS IN PATIENTS WITH HIGH-RISK MYELODISPLASTIC SYNDROMES TREATED WITH INTENSIVE CHEMOTHERAPY

Caballero, J. C.; Sánchez, J. M. Hernández; Abáigar, M.; More

HemaSphere. 3(S1):937-938, June 2019.

PS1214 INFECTIOUS COMPLICATIONS FOLLOWING ARI-0001 CELL (A3B1:CD8:4–1BB:CD3Z CART19) TREATMENT IN ADULT AND PEDIATRIC PATIENTS WITH CD19+ RELAPSED / REFRACTORY MALIGNANCIES

Ortiz-Maldonado, V.; Alonso-Saladrigues, A.; Cardozo, C.; More

HemaSphere. 3(S1):553-554, June 2019.

S1636 FRACTIONATED DOSING OF ARI-0001 CELLS (A3B1:CD8:4–1BB:CD3Z CAR19) AND EARLY TOCILIZUMAB ADMINISTRATION MAY REDUCE THE INCIDENCE OF SEVERE CYTOKINE RELEASE SYNDROME IN PATIENTS WITH CD19+ MALIGNANCIES

Ortiz-Maldonado, V.; Alonso-Saladrigues, A.; Caballero-Baños, M.; More

HemaSphere. 3(S1):756, June 2019.

PS1080 LYMPHOMA ASSOCIATED HEMOPHAGOCYTIC SYNDROME: A SINGLE-CENTER EXPERIENCE

Rojas Martínez, J.A.; Prats-Martín, C.; Pérez Ortega, L.; More

HemaSphere. 3(S1):489-490, June 2019.

PB1857 THE ROLE OF WHOLE-BODY MAGNETIC RESONANCE IMAGING IN THE DETECTION OF VASCULAR EVENTS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA.

Navarro-Almenzar, B.; Salido Fiérrez, E.; Cabañas Perianes, V.; More

HemaSphere. 3(S1):847, June 2019.

PS943 SAFETY AND EFFICACY OF TISAGENLECLEUCEL (CTL019) IN B ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS: ROBERT DEBRÉ AND SAINT LOUIS HOSPITALS EXPERIENCE

Dourthe, M.E.; Cabannes-Hamy, A.; Yakouben, K.; More

HemaSphere. 3(S1):425, June 2019.

Author:
Cabarkapa, V.
Author:
Cabero, A.

PF757 REDUCED INTENSITY CONDITIONING AND AVOIDING USE OF BROAD SPECTRUM ANTIBIOTHERAPY ACTIVE AGAINST GRAM-NEGATIVE BACTERIA MIGHT HAVE A CUMULATIVE IMPACT IN REDUCING INTESTINAL MICROBIOTA MISBALANCE

Espigado, I.; Rodriguez, N.; Labrador, G.; More

HemaSphere. 3(S1):332-333, June 2019.

PB2350 EFFICACY AND SAFETY OF POST HEMATOPOIETIC STEM CELL TRANSPLANTATION DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH ACUTE LEUKEMIA. RETROSPECTIVE ANALYSIS IN OUR CENTER

Romero, Y. Gonzalez; Mora, J.; Cortes, M. A.; More

HemaSphere. 3(S1):1047, June 2019.

Author:
Cabiati, B.

PF436 GMP MANUFACTURING OF ALLOGENEIC CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) CYTOKINE INDUCED KILLER (CIK) CELLS WITH SLEEPING BEAUTY (SB) TRANSPOSON FOR ADOPTIVE IMMUNOTHERAPY

Magnani, C.F.; Gaipa, G.; Belotti, D.; More

HemaSphere. 3(S1):171, June 2019.

Author:
Cabral, R.

PF307 POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN LIVER AND KIDNEY TRANSPLANT RECIPIENTS OVER 33 YEARS: A SINGLE-CENTRE EXPERIENCE

Lopes, M.S.; Neto, M.; Cabral, R.; More

HemaSphere. 3(S1):106, June 2019.

Author:
Cabras, A.

PF472 VERY LATE REALAPSES (VLR) ≥5 YEARS AFTER INITIAL TREATMENT WITH CHEMOTHERAPY±RADIOTHERAPY (CT±RT) IN HODGKIN LYMPHOMA (HL): A JOIN STUDY ON TREATMENT STRATEGIES AND PROGNOSTIC FACTORS FOR THE OUTCOME

Vassilakopoulos, T.; Liaskas, A.; Rizzuto, G.; More

HemaSphere. 3(S1):187-188, June 2019.

Author:
Cabras, M.G.

S1597 PET-DRIVEN RADIOTHERAPY IN PATIENTS WITH LOW RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): THE DLCL10 MULTICENTER PHASE 2 TRIAL BY FONDAZIONE ITALIANA LINFOMI (FIL)

Balzarotti, M.; Spina, M.; Monagheddu, C.; More

HemaSphere. 3(S1):735, June 2019.

Author:
Cabrera, A.

PB1739 SURVIVAL ANALYSIS OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH INTENSIVE CHEMOTHERAPY: RESULTS OF A MEXICAN NATIONAL AML REGISTRY.

Demichelis, R.; Zapata, N.; Leyto, F.; More

HemaSphere. 3(S1):800, June 2019.

PB1773 OVERAL SURVIVAL OF MEXICAN NATIONAL REGISTRY OF ACUTE PROMYEOLOCYTIC LEUKEMIA, AN ANALYSIS OF 324 CASES

Zapata, N.; Montaño, E.; Ramos, C.; More

HemaSphere. 3(S1):814, June 2019.

Author:
Cabrera, W.
Author:
Cacciola, E.
Author:
Cacciola, R.

PS1468 IMPACT OF CYTOREDUCTIVE DRUGS ON SECOND CANCER IN MYELOPROLIFERATIVE NEOPLASMS

Barbui, T.; Ghirardi, A.; Masciulli, A.; More

HemaSphere. 3(S1):667-668, June 2019.

Author:
Cachat, F.
Author:
Cacheux, V.

S103 OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL - A LYSA TRIAL

Legouill, S.; Beldi-Ferchiou, A.; Cacheux, V.; More

HemaSphere. 3(S1):3, June 2019.

PB1660 FLOW CYTOMETRY CHALLENGE FOR MEASURABLE RESIDUAL DISEASE MONITORING IN B-ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PATIENTS RECEIVING TARGETED IMMUNOTHERAPY

Bermejo, A. Yeguas; García-Sancho, A. Martín; Morón, N. Puig; More

HemaSphere. 3(S1):768, June 2019.

PB2080 ROLE OF SOMATIC MUTATIONS IN PATIENTS WITH HIGH-RISK MYELODISPLASTIC SYNDROMES TREATED WITH INTENSIVE CHEMOTHERAPY

Caballero, J. C.; Sánchez, J. M. Hernández; Abáigar, M.; More

HemaSphere. 3(S1):937-938, June 2019.

Author:
Cadievski, L.
Author:
Caers, J.

S122 THE FIRST-IN-CLASS, ORALLY AVAILABLE BMI-1 MODULATORS PTC-028 AND PTC596 DISPLAY POTENT ACTIVITY IN PRE-CLINICAL MODELS OF MULTIPLE MYELOMA

Bolomsky, A.; Muller, J.; Stangelberger, K.; More

HemaSphere. 3(S1):13, June 2019.

Author:
Cafforio, L.

PF365 PROGNOSTIC IMPLICATIONS OF IGHV GENE REARRANGEMENTS WITH “BORDERLINE” PERCENTAGE OF MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

Raponi, S.; Ilari, C.; Della Starza, I.; More

HemaSphere. 3(S1):134-135, June 2019.

Author:
Caforio, M.
Author:
Cafro, A.
Author:
Cafro, A.M.

PF579 TUMOR CIRCULATING PLASMA CELLS DETECTED BY FLOW CYTOMETRIC SINGLE PLATFORM METHOD ARE RELATED TO NEGATIVE PATIENTS‘ CHARACTERISTICS IN MULTIPLE MYELOMA

Muccio, V.E.; Gilestro, M.; Saraci, E.; More

HemaSphere. 3(S1):241-242, June 2019.

Author:
Cagnetta, A.

PB1730 A SIMPLE FLOW CYTOMETRY-BASED SCORE MAY OPTIMIZE TESTING FOR BIALLELIC CEBPA MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA PATIENTS

Marcolin, R.; Guolo, F.; Minetto, P.; More

HemaSphere. 3(S1):796, June 2019.

Author:
Cahn, J.-Y.

PS993 DE NOVO ADULT ACUTE MYELOID LEUKEMIA PATIENTS DISPLAY AT DIAGNOSIS FUNCTIONAL DEREGULATION OF REDOX BALANCE CORRELATED WITH MOLECULAR SUBTYPES AND OVERALL SURVIVAL

Mondet, J.; Presti, C. Lo; Garrel, C.; More

HemaSphere. 3(S1):446-447, June 2019.

Author:
Cai, X.

PF805 INCIDENCE, CLINICAL FEATURES, RISK FACTORS AND OUTCOMES OF REFRACTORY ACQUIRED IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: A CHINESE MULTI-CENTER EXPERIENCE

Gui, R.-Y.; Zhang, G.-C.; Wang, C.-C.; More

HemaSphere. 3(S1):355, June 2019.

PS1558 COMPARISON OF THE INCIDENCE AND OUTCOMES OF TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY BETWEEN HAPLOIDENTICAL AND MATCHED SIBLING DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION

Gui, R.-Y.; Liu, X.; Su, Y.; More

HemaSphere. 3(S1):718-719, June 2019.

PB2361 INCIDENCE, RISK FACTORS AND OUTCOMES OF SINUSOIDAL OBSTRUCTION SYNDROME AFTER HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION

Cai, X.; Wu, J.; Gui, R.-Y.; More

HemaSphere. 3(S1):1052, June 2019.

Author:
Cai, Y.

S1613 ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION CAN ABROGATE INCREASING RISK OF RELAPSE FROM PERSISTENT MUTATIONS MEASURED BY TARGETED SEQUENCING AT REMISSION IN NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA

Kim, T.; Ahn, J.-S.; Jung, S.-H.; More

HemaSphere. 3(S1):743-744, June 2019.

PS943 SAFETY AND EFFICACY OF TISAGENLECLEUCEL (CTL019) IN B ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS: ROBERT DEBRÉ AND SAINT LOUIS HOSPITALS EXPERIENCE

Dourthe, M.E.; Cabannes-Hamy, A.; Yakouben, K.; More

HemaSphere. 3(S1):425, June 2019.

Author:
Caillon, H.

S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS

Moreau, P.; Attal, M.; Hulin, C.; More

HemaSphere. 3(S1):24-25, June 2019.

Author:
Caillot, D.

S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS

Moreau, P.; Attal, M.; Hulin, C.; More

HemaSphere. 3(S1):24-25, June 2019.

PF592 IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA

Hulin, C.; Facon, T.; Kumar, S.; More

HemaSphere. 3(S1):248-249, June 2019.

PF594 BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE VS BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION: INTEGRATED ANALYSIS OF RANDOMIZED CONTROLLED TRIALS IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

Rosiñol, L.; Hebraud, B.; Oriol, A.; More

HemaSphere. 3(S1):249-250, June 2019.

PF598 STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY

Hulin, C.; Moreau, P.; Attal, M.; More

HemaSphere. 3(S1):252, June 2019.

Author:
Cain, L.

PF626 HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUTCOMES OF ORAL IXAZOMIB MAINTENANCE THERAPY POST AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) FROM TOURMALINE-MM3

Schjesvold, F.; Goldschmidt, H.; Maisnar, V.; More

HemaSphere. 3(S1):266-267, June 2019.

Author:
Caini, M.
Author:
Cairns, D.

S873 EFFICACY OF QUADRUPLET KCRD (CARFILZOMIB, CYCLOPHOSPHAMIDE, LENALIDOMIDE AND DEXAMETHASONE) INDUCTION FOR NEWLY DIAGNOSED MYELOMA PATIENTS: ANALYSIS OF THE MYELOMA XI STUDY BY MOLECULAR RISK

Pawlyn, C.; Kaiser, M.; Davies, F.; More

HemaSphere. 3(S1):391, June 2019.

Author:
Cairo, S.
Author:
Cairoli, R.

PF529 PROGNOSTIC CORRELATION OF CELL-OF-ORIGIN AND MYC, BCL-2 AND BCL-6 STATUS IN HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS

Crucitti, L.; Rusconi, C.; Re, A.; More

HemaSphere. 3(S1):217, June 2019.

Author:
Caja, T.
Author:
Cakar, M. Kizil
Author:
Cake, S.

PS1068 SAFETY ANALYSIS OF AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP NHL29: A PHASE II STUDY OF IBRUTINIB, RITUXIMAB AND MINI-CHOP IN VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMA

Verner, E.; Johnston, A.; Pati, N.; More

HemaSphere. 3(S1):483-484, June 2019.

Author:
calabrese, C.
Author:
Calabresi, L.
Author:
Calabretto, G.

PS1145 TARGETED ACTIVATION OF THE PROTEIN PHOSPHATASES SHP-1 AND PP2A ABROGATES CONSTITUTIVE ACTIVATION OF SURVIVAL PATHWAYS IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA (LGLL)

Pagano, M.A.; Tibaldi, E.; Brunati, A.M.; More

HemaSphere. 3(S1):518-519, June 2019.

PS1431 IDENTIFICATION OF THE TRUE HYPERDIPLOID MULTIPLE MYELOMA SUBSET BY COMBINING CONVENTIONAL KARYOTYPING AND FISH ANALYSIS

Barila’, G.; Bonaldi, L.; Martines, A.; More

HemaSphere. 3(S1):659, June 2019.

Author:
Calabrò, M.

S840 IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA – A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP

Pleyer, L.; Leisch, M.; Kouraklis, A.; More

HemaSphere. 3(S1):374-375, June 2019.

Author:
Calafiore, V.

PB2123 FEASIBILITY, TOLERABILITY AND EFFICACY OF CARFILZOMIB, LENALIDOMIDE AND DESAMETHASONE(KRD) IN RELAPSED REFRACTORY MYELOMA PATIENTS: A REAL-LIFE SURVEY OF THE SICILIAN MYELOMA NETWORK

Conticello, C.; Martino, E.; Calafiore, V.; More

HemaSphere. 3(S1):956, June 2019.

Author:
Calaminici, M.

PF513 MUTATIONS AFFECTING THE CREBBP HAT DOMAIN PREDICT RESPONSE TO MTOR INHIBITORS EVEROLIMUS AND TEMSIROLIMUS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

Kumar, E.; Korfi, K.; Bewicke-Copley, F.; More

HemaSphere. 3(S1):209, June 2019.

Author:
Calasanz, M.-J.

S871 CURATIVE STRATEGY (GEM-CESAR) FOR HIGH-RISK SMOLDERING MYELOMA: CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (KRD) AS INDUCTION FOLLOWED BY HDT-ASCT, CONSOLIDATION WITH KRD AND MAINTENANCE WITH RD

Mateos, M.-V.; Martínez-López, J.; Rodríguez-Otero, P.; More

HemaSphere. 3(S1):390, June 2019.

Author:
Calasanz, M.J.